about
Pharmacotherapies for obesity: past, current, and future therapiesTesofensine, a novel triple monoamine reuptake inhibitor, induces appetite suppression by indirect stimulation of alpha1 adrenoceptor and dopamine D1 receptor pathways in the diet-induced obese ratChronic 5-HT6 receptor modulation by E-6837 induces hypophagia and sustained weight loss in diet-induced obese ratsSibutramine reduces feeding, body fat and improves insulin resistance in dietary-obese male Wistar rats independently of hypothalamic neuropeptide YCombinations of drugs in the Treatment of Obesity.Simultaneous determination of sibutramine and its active metabolites in human plasma by LC-MS/MS and its application to a pharmacokinetic study.Proteome changes in rat plasma in response to sibutramine.Mitochondrial uncoupling as a target for drug development for the treatment of obesity.Assessment of acute and chronic pharmacological effects on energy expenditure and macronutrient oxidation in humans: responses to ephedrineDrug treatment of obesity: from past failures to future successes?Efficacy and tolerability of the association of sibutramine and orlistat for six months in overweight and obese patientsCurrent and investigational antiobesity agents and obesity therapeutic treatment targets.The "Skinny" on brown fat, obesity, and bone.The use of serotonergic drugs to treat obesity--is there any hope?An assessment of the safety and efficacy of sibutramine, an anti-obesity drug with a novel mechanism of action.Anti-obesity drug development.The utility of animal models to evaluate novel anti-obesity agents.Central nervous system regulation of brown adipose tissue.Central serotonergic neurons activate and recruit thermogenic brown and beige fat and regulate glucose and lipid homeostasis.Idalopirdine - a small molecule antagonist of 5-HT6 with therapeutic potential against obesity.Investigational therapies in the treatment of obesity.Detection of thermogenesis in rodents in response to anti-obesity drugs and genetic modification.Phentermine, sibutramine and affective disorders.The effects of pharmacologic agents for type 2 diabetes mellitus on body weight.Neuropsychiatric adverse effects of centrally acting antiobesity drugs.Effects of the cannabinoid CB1 receptor antagonist SR141716 on oxygen consumption and soleus muscle glucose uptake in Lep(ob)/Lep(ob) mice.Effects of oral anorexiant sibutramine on the expression of cytochromes P450s in human hepatocytes and cancer cell lines.Treatment effect of sibutramine compared to fluoxetine on leptin levels in polycystic ovary disease.The effect of the triple monoamine reuptake inhibitor tesofensine on energy metabolism and appetite in overweight and moderately obese men.Evaluation of anti-obesity activity of duloxetine in comparison with sibutramine along with its anti-depressant activity: an experimental study in obese rats.Rapid screening of illicit additives in weight loss dietary supplements with desorption corona beam ionisation (DCBI) mass spectrometry.Influence of sibutramine on energy expenditure in African American women.Regulation of body weight and carcass composition by sibutramine in rats.Sibutramine decreases body weight gain and increases energy expenditure in obese Zucker rats without changes in NPY and orexins.Inverse agonism at α2A adrenoceptors augments the hypophagic effect of sibutramine in rats.The novel antiobesic HMR1426 reduces food intake without affecting energy expenditure in rats.The stereoselective biotransformation of the anti-obesity drug sibutramine in rat liver microsomes and in primary cultures of rat hepatocytes.Fluoxetine induces lean phenotype in rat by increasing the brown/white adipose tissue ratio and UCP1 expression.Sibutramine alters the central mechanisms regulating the defended body weight in diet-induced obese rats.Comparison of the effects of sibutramine and other weight-modifying drugs on extracellular dopamine in the nucleus accumbens of freely moving rats.
P2860
Q21296814-C5BA44C9-B36F-4462-9456-9F616B3EBD38Q24602893-848B1CC0-BE6B-44E2-9A4A-D54B612BB1C5Q24675513-FFF2A43A-A36F-4497-A0AE-FDEE3899F454Q28363106-5AAB1788-A26F-4ABF-BC34-192ECA1CCE50Q33664063-10E5E803-3EB6-4B5F-A8FA-64E965D0DD16Q33811844-0600CAD1-BEDD-465E-91B6-FAFC94F3B3F0Q33825506-50F7B432-CB46-4FE2-A667-29C5F6E6A65BQ33960204-EECBAA26-2989-4375-8408-7B09E3F0FF5DQ34097378-094499AA-8AB8-4EDA-A80A-E477E09FC813Q34135268-1BFA61A3-076C-4BED-99A4-8F9334A466DDQ34143583-8A201956-00CA-4F7E-A5D7-3EBD03B15E97Q34344786-824CC7D3-5FE4-434E-A979-4E5B97BBBE48Q34447429-9C92D5F9-4963-4F4E-A757-A8650730BD95Q34712327-E83C1FBE-F1CC-4DB2-A9BE-29FA755EC97AQ34742716-D67508B9-0DE8-4D7F-BE84-F7C2EDA85AAFQ34841680-52F93D1B-14CD-42CA-9C0F-93AD4B5A29D0Q35589958-97B48F24-633C-40AE-8FFF-151F5A004B3AQ35618665-4330DA2E-F76D-4412-809E-4737780716E9Q36045572-2229FAEE-9269-405F-9CFE-4AFB50F96715Q36273778-FBB3602C-DB10-47B5-BFE8-90137F38CA86Q36543067-3D522654-D0E4-4C7F-B3C0-6507C195CA60Q36746883-0411CB8A-3194-4707-BAA5-043D47264B27Q36832356-01403C6F-6AE3-4351-9AF0-EBB82486CAD2Q37226372-E5B4B84D-0C51-4128-9430-0749969A6128Q37939362-E3360E41-2C63-4FA3-A129-FB4D207FCA54Q38333962-8C7B95A5-1A32-48EB-A7C0-61108ECA5E23Q39095674-2F0ACEC4-8B98-44CC-A0C4-A60A51F5D6A0Q42474617-0AFF45F8-BE32-4369-BA4C-B28DC6A1FD97Q43060939-09A0D5BE-D307-47BD-A0FB-C7365CD7DD3BQ43236354-6BA3DB7F-F547-4620-AC94-1FFE3C963DC6Q43346587-759E8AFA-B2CE-49A0-A9AA-F79421C25B1AQ43594329-CCCC2FBF-4A5F-41BB-8C52-CB8092DFE88BQ43911362-75A573B5-67D6-4FE5-8B7E-C1CE313B80B8Q44424188-28DEE5A8-FD7D-40B3-802F-633FEBA8B0E3Q44452598-A039F96A-A913-4D57-9515-63781F6E5BDAQ45038784-45FB07AC-9E4A-42E9-BBCB-A5ED4A0198D0Q46419827-8F075B02-C2CA-4D9B-BC2E-7706A2C08BCBQ46707110-22F16F6F-7359-4250-B070-D94DA3886AACQ47225467-EEFE75ED-6A80-4213-9F1C-884D4FA1EA6EQ47228069-9E4AD105-982A-46BF-BB92-9DF8F5507895
P2860
description
1999 nî lūn-bûn
@nan
1999 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի մարտին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Thermogenic effects of sibutramine and its metabolites.
@ast
Thermogenic effects of sibutramine and its metabolites.
@en
type
label
Thermogenic effects of sibutramine and its metabolites.
@ast
Thermogenic effects of sibutramine and its metabolites.
@en
prefLabel
Thermogenic effects of sibutramine and its metabolites.
@ast
Thermogenic effects of sibutramine and its metabolites.
@en
P2093
P2860
P356
P1476
Thermogenic effects of sibutramine and its metabolites.
@en
P2093
P2860
P304
P356
10.1038/SJ.BJP.0702446
P407
P577
1999-03-01T00:00:00Z